The news is by your side.

haemophilia group

Sanofi digs deep to buy US haemophilia group Bioverativ for $11.6 billion

PARIS: French healthcare group Sanofi has agreed to buy US haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases. Sanofi shares fell 3.4 percent by 0920 GMT, making the stock the worst performer on France‚Äôs benchmark CAC-40 index and several analysts deemed the deal expensive. The move comes at a time of renewed interest by large drugmakers in smaller biotech firms and predictions by some experts that 2018 will…